ClinConnect ClinConnect Logo
Search / Trial NCT06855043

Little Lungs Study

Launched by UNIVERSITY OF WISCONSIN, MADISON · Feb 25, 2025

Trial Information

Current as of June 27, 2025

Not yet recruiting

Keywords

Premature Birth

ClinConnect Summary

The Little Lungs Study is a clinical trial designed to test a new treatment for extremely premature infants who are having serious breathing difficulties and need help from a machine to breathe (this is called invasive mechanical ventilation). Specifically, the study looks at whether a combination of two medications, late surfactant treatment and budesonide, can improve the babies' breathing and whether this treatment is safe. The trial will involve giving participants three doses of the study drug over time.

To be eligible for the study, infants must be between 7 to 14 days old, born very prematurely (between 22 and 28 weeks of pregnancy), and require mechanical support for their breathing. Parents or guardians must be able to give permission for their child to join the study and should speak either English or Spanish. It's important to note that some infants may not qualify if they have certain health issues or if their breathing problems are not severe enough. If your baby is eligible and joins the study, they will receive the new treatment, and the research team will closely monitor their health throughout the trial.

Gender

ALL

Eligibility criteria

  • Neonate Inclusion Criteria:
  • Gestational age 22 0/7 to 28 6/7 weeks at birth
  • Age 7-14 days
  • Need invasive mechanical ventilatory support
  • Have at least one parent/guardian who is able to provide parental permission in English or Spanish
  • Birthing Parent Inclusion Criteria:
  • Have a baby who meets neonate eligibility criteria and enrolls in the study.
  • Is able to provide consent in English or Spanish
  • Neonate Exclusion Criteria:
  • Major congenital anomalies
  • History of pulmonary hemorrhage
  • Antibiotic use within 48 hours
  • Prior treatment with corticosteroids for prevention of lung disease
  • Indomethacin or Ibuprofen use within 72 hours
  • Have a birth parent aged less than 18 years
  • Respiratory severity score less than 2.4
  • Not expected to survive for greater than 7 days at enrollment
  • Birthing Parent Exclusion Criteria:
  • Is aged less than 18 years

About University Of Wisconsin, Madison

The University of Wisconsin-Madison is a leading research institution renowned for its commitment to advancing healthcare through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources, including cutting-edge facilities and a diverse pool of expert researchers, to conduct rigorous studies that address critical health challenges. The institution's focus on translating research findings into practical applications fosters the development of new treatments and interventions, ultimately contributing to improved patient outcomes and public health initiatives. As a sponsor of clinical trials, the University of Wisconsin-Madison is dedicated to upholding the highest ethical standards and ensuring participant safety throughout the research process.

Locations

Madison, Wisconsin, United States

Madison, Wisconsin, United States

Patients applied

0 patients applied

Trial Officials

Dinushan Kaluarachchi, MBBS

Principal Investigator

University of Wisconsin, Madison

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported